Therapeutic Efficacy and Safety of Intense Pulsed Light for Meibomian Gland Dysfunction in Patients with Chronic Ocular Graft-Versus-Host Disease.

IF 2.6 4区医学 Q2 OPHTHALMOLOGY Ocular Immunology and Inflammation Pub Date : 2024-10-01 Epub Date: 2023-10-20 DOI:10.1080/09273948.2023.2266763

Xi Song, Ziyan Chen, Jing Li, Shaowen Wu, Lingyi Liang

{"title":"Therapeutic Efficacy and Safety of Intense Pulsed Light for Meibomian Gland Dysfunction in Patients with Chronic Ocular Graft-Versus-Host Disease.","authors":"Xi Song, Ziyan Chen, Jing Li, Shaowen Wu, Lingyi Liang","doi":"10.1080/09273948.2023.2266763","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the efficacy and safety of intense pulsed light combined with meibomian gland expression (IPL-MGX) for treating meibomian gland dysfunction (MGD) associated with chronic ocular graft-versus-host disease (oGVHD).Methods: This retrospective study included 18 patients (18 eyes) with Fitzpatrick skin type ≤ IV, who underwent 3 to 8 sessions of IPL-MGX. Dry eye symptomology, ocular surface parameters, and adverse events were evaluated.Results: Of 18 eyes, 83.3% and 66.7% showed severe oGVHD and severe MGD, respectively. At 4 weeks after the final session, significant improvements in the OSDI (P < 0.001), SPEED (P = 0.001), meibum expressibility (P < 0.001), and meibum quality (P = 0.016) were observed. At 12 weeks after, the OSDI (P = 0.009), SPEED (P = 0.002), and meibum expressibility (P = 0.008) significantly improved. No adverse events owing to IPL were reported.Conclusion: IPL-MGX may improve the ocular symptoms, ameliorate meibomian gland secretion, and is considered as a safe treatment for MGD in oGVHD patients.","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Immunology and Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09273948.2023.2266763","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the efficacy and safety of intense pulsed light combined with meibomian gland expression (IPL-MGX) for treating meibomian gland dysfunction (MGD) associated with chronic ocular graft-versus-host disease (oGVHD).

Methods: This retrospective study included 18 patients (18 eyes) with Fitzpatrick skin type ≤ IV, who underwent 3 to 8 sessions of IPL-MGX. Dry eye symptomology, ocular surface parameters, and adverse events were evaluated.

Results: Of 18 eyes, 83.3% and 66.7% showed severe oGVHD and severe MGD, respectively. At 4 weeks after the final session, significant improvements in the OSDI (P < 0.001), SPEED (P = 0.001), meibum expressibility (P < 0.001), and meibum quality (P = 0.016) were observed. At 12 weeks after, the OSDI (P = 0.009), SPEED (P = 0.002), and meibum expressibility (P = 0.008) significantly improved. No adverse events owing to IPL were reported.

Conclusion: IPL-MGX may improve the ocular symptoms, ameliorate meibomian gland secretion, and is considered as a safe treatment for MGD in oGVHD patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

强脉冲光治疗慢性眼部移植物抗宿主病患者睑板腺功能障碍的疗效和安全性。

目的：评价强脉冲光联合睑板腺表达（IPL-MGX）治疗慢性眼部移植物抗宿主病（oGVHD）相关的睑板腺功能障碍（MGD）的疗效和安全性。评估干眼症症状、眼表参数和不良事件。结果：在18只眼睛中，83.3%和66.7%的眼睛表现为严重oGVHD和严重MGD。在最后一次治疗后4周，观察到OSDI（P＜0.001）、SPEED（P＝0.001）、meibum表达能力（P＜001）和meibum质量（P＝0.016）有显著改善。术后12周，OSDI（P=0.009）、SPEED（P=0.002）和meibum表达能力（P=0.008）显著改善。未报告因IPL引起的不良事件。结论：IPL-MGX可改善眼部症状，改善睑板腺分泌，是治疗oGVHD患者MGD的安全方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Ocular Immunology and Inflammation 医学-眼科学

CiteScore

6.20

自引率

15.20%

发文量

285

审稿时长

6-12 weeks

期刊介绍： Ocular Immunology & Inflammation ranks 18 out of 59 in the Ophthalmology Category.Ocular Immunology and Inflammation is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and vision scientists. Published bimonthly, the journal provides an international medium for basic and clinical research reports on the ocular inflammatory response and its control by the immune system. The journal publishes original research papers, case reports, reviews, letters to the editor, meeting abstracts, and invited editorials.

期刊最新文献

Acinetobacter baumannii Endogenous Endophthalmitis Presenting with Iris Nodules. Autoimmune Retinopathy Following COVID-19: A Case Report. Helicobacter pylori and Its Treatment Impact on Immune-Mediated Ocular Diseases. Epidemiology of Intermediate Uveitis. Limited Utility of Keratic Precipitate Morphology as an Indicator of Underlying Diagnosis in Ocular Inflammation.